+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cardiomyopathy Therapies Market 2019-2023 - Product Image

Global Cardiomyopathy Therapies Market 2019-2023

  • ID: 4720689
  • Report
  • Region: Global
  • 108 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • MORE
About this market

Advent of genomic medicine to push market growth during the forecast period. Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. The analysts have predicted that the cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.

Market Overview

Initiative to increase awareness about disease

There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.

High cost of treatment

Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the cardiomyopathy therapies market during the 2019-2023, view the report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of several companies including Merck and Sanofi, the competitive environment is quite intense. Factors such as the advent of genomic medicine and the initiative to increase awareness about disease, will provide considerable growth opportunities to cardiomyopathy therapies manufactures. AstraZeneca, Merck, Pfizer, and Sanofi are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Dilated cardiomyopathy - Market size and forecast 2018-2023
  • Hypertrophic cardiomyopathy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Market trends
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global CVD treatment market
Exhibit 03: Segments of global CVD treatment market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Threat of rivalry
Exhibit 14: Market condition - Five forces 2018
Exhibit 15: Type - Market share 2018-2023 (%)
Exhibit 16: Comparison by type
Exhibit 17: Dilated cardiomyopathy - Market size and forecast 2018-2023 ($ millions)
Exhibit 18: Dilated cardiomyopathy - Year-over-year growth 2019-2023 (%)
Exhibit 19: Hypertrophic cardiomyopathy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Hypertrophic cardiomyopathy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Others - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Decision framework
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: AstraZeneca - Vendor overview
Exhibit 43: AstraZeneca - Business segments
Exhibit 44: AstraZeneca - Organizational developments
Exhibit 45: AstraZeneca - Geographic focus
Exhibit 46: AstraZeneca - Key offerings
Exhibit 47: Merck - Vendor overview
Exhibit 48: Merck - Business segments
Exhibit 49: Merck - Organizational developments
Exhibit 50: Merck - Segment focus
Exhibit 51: Merck - Key offerings
Exhibit 52: Pfizer - Vendor overview
Exhibit 53: Pfizer - Business segments
Exhibit 54: Pfizer - Organizational developments
Exhibit 55: Pfizer - Geographic focus
Exhibit 56: Pfizer - Segment focus
Exhibit 57: Pfizer - Key offerings
Exhibit 58: Sanofi - Vendor overview
Exhibit 59: Sanofi - Business segments
Exhibit 60: Sanofi - Organizational developments
Exhibit 61: Sanofi - Segment focus
Exhibit 62: Sanofi - Key offerings
Exhibit 63: Validation techniques employed for market sizing
Exhibit 64: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • MORE
Global Cardiomyopathy Therapies Market 2019-2023

The author of the report recognizes the following companies as the key players in the global cardiomyopathy therapies market: AstraZeneca, Merck, Pfizer, and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of genomic medicine.”

According to the report, one of the major drivers for this market is the initiative to increase awareness about disease.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4720689
Adroll
adroll